Q3 2024 Voyager Therapeutics Inc Earnings Call Transcript
Key Points
- Voyager Therapeutics Inc (VYGR) completed enrollment and dosing in the single ascending dose trial of VY7523, their anti-tau antibody for Alzheimer's disease.
- The company has a strong cash position of $345 million, expected to provide financial runway into 2027.
- Voyager Therapeutics Inc (VYGR) has established blue-chip partnerships with leading companies like Neurocrine, Novartis, and Alexion, with recent expansions in these collaborations.
- The TRACER platform for discovering novel AAV capsids is progressing well, with expectations for IMDs for three programs next year.
- Encouraging third-party data supports the potential of their anti-tau antibody approach, reinforcing confidence in their Alzheimer's disease program.
- The primary endpoint was not met in the full study population for the bepranemab clinical trial, which could impact perceptions of similar approaches.
- Voyager Therapeutics Inc (VYGR) is still in preclinical stages for their blood-brain shuttle programs, with no clear timeline for clinical entry.
- There is uncertainty in translating tau PET imaging results into cognitive improvements, which remains a challenge for the Alzheimer's program.
- The tau-silencing gene therapy program is not expected to file for US IND and Health Canada CTA until 2026, indicating a longer timeline for development.
- The company faces risks and uncertainties that could materially affect actual results, as highlighted in their forward-looking statements.
Good afternoon and welcome to the Voyager Therapeutics third-quarter 2024 financial results conference call. (Operator Instructions) Please note that today's call is being recorded. A replay of today's call will be available on the Investors section of the company website approximately two hours after completion of this call.
I would now like to turn the call over to Trista Morrison, Chief Corporate Affairs Officer at Voyager.
Thank you, and good afternoon. We issued our third-quarter 2024 financial results press release this afternoon. The press release and 10-Q are available on our website. Joining me on today's call are Dr. Al Sandrock, our Chief Executive Officer; and Dr. Todd Carter, our Chief Scientific Officer. We will also be joined for the Q&A portion of the call by Nathan Jorgensen, our Chief Financial Officer.
Before we get started, I would like to remind everyone that during this call, Voyager representatives may make
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
